Gram-positive bacterial infections
Conditions
Interventions
Linezolid tablets/injections are initiated as standard treatment based on the physician's decision (typically 1200 mg/day). In cases where oral administration is not feasible due to gastrointestinal a
Sponsors
Hashimoto Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Intervention Group 1. Patients receiving inpatient or outpatient care at Tsukuba University Hospital, Hitachi General Hospital, or Tsukuba Medical Center Hospital 2. Patients scheduled to receive linezolid for 7 days or more 3. Patients who underwent blood tests between 3 days prior to and the day of linezolid initiation 4. Patients with platelet count or more 75000/micro liter at linezolid initiation 5. Patients within 3 days after linezolid initiation 6. Patients who provided written informed concent either personally or through a proxy (limited to relatives) Control Group 1. Patients who received linezolid for 7 days or more at Tsukuba University Hospital, Hitachi General Hospital, or Tsukuba Medical Center Hospital between January 2015 and May 2023 2. Patients who underwent blood tests between 3 days prior to and the day of linezolid initiation 3. Patients with platelet count or more 75000/micro liter at linezolid initiation
Exclusion criteria
Exclusion criteria: 1) Patients deemed inappropriate for this study by the investigators 2) Patients who refused enrollment in the opt-out study (control group)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to onset of thrombocytopenia after linezolid initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time to onset of severe thrombocytopenia after linezolid initiation 2. Incidence rate of severe thrombocytopenia during the linezolid treatment period 3. Incidence rate of thrombocytopenia on days 3, 7+-1, 14+-2, and 28+-2 from linezolid initiation 4. Incidence rate of severe thrombocytopenia on days 3, 7+-1, 14+-2, and 28+-2 from linezolid initiation 5. Mortality rate at 30 days from linezolid initiation 6. Treatment success rate at 30 days from linezolid initiation 7. Discontinuation rate of linezolid due to adverse events 8. Duration of linezolid administration 9. Serum concentration of linezolid 10. Daily dose and cost of linezolid administration 11. Immature platelet count and reticulocyte count on days 3, 7+-1, 14+-2, and 28+-2 from linezolid initiation | — |
Contacts
Public ContactNaoaki Hashimoto
University of Tsukuba Hospital
Outcome results
None listed